SGLT2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy

SGLT2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy

Background: Elevated myocardial intracellular sodium ([Na+]i) was shown to decrease mitochondrial calcium ([Ca2+]MITO) via mitochondrial sodium/calcium exchanger (NCXMITO), resulting in decreased mitochondrial ATP synthesis. The sodium-glucose co-transporter 2 inhibitor (SGLT2i) ertugliflozin (ERTU)...

Full description

Bibliographic Details
Main Authors:	Dominique Croteau, Tomas Baka, Sara Young, Huamei He, Jordan M. Chambers, Fuzhong Qin, Marcello Panagia, David R. Pimentel, James A. Balschi, Wilson S. Colucci, Ivan Luptak
Format:	Article
Language:	English
Published:	Elsevier 2023-04-01
Series:	Biomedicine & Pharmacotherapy
Subjects:	Cardiac energetics Contractile function Diabetic cardiomyopathy Ertugliflozin Myocardial intracellular sodium Sodium-glucose co-transporter 2 (SGLT2) inhibitor
Online Access:	http://www.sciencedirect.com/science/article/pii/S0753332223000987

Similar Items

Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes
by: Derosa G, et al.
Published: (2018-09-01)

Effects of Sodium‐Glucose Linked Transporter 2 Inhibition With Ertugliflozin on Mitochondrial Function, Energetics, and Metabolic Gene Expression in the Presence and Absence of Diabetes Mellitus in Mice
by: Dominique Croteau, et al.
Published: (2021-07-01)

New SGLT2 inhibitor ertugliflozin: safe and effective in the management of type 2 diabetes
by: V. V. Salukho, et al.
Published: (2020-05-01)

Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism
by: Elmar Zügner, et al.
Published: (2022-07-01)

Ertugliflozin in the treatment of type 2 diabetes mellitus
by: Joel C Marrs, et al.
Published: (2020-11-01)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
by: Simes BC, et al.
Published: (2019-10-01)

Neutral effects of SGLT2 inhibitors in acute coronary syndromes, peripheral arterial occlusive disease, or ischemic stroke: a meta-analysis of randomized controlled trials
by: Pei-Chien Tsai, et al.
Published: (2023-03-01)

Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials
by: Jie Liu, et al.
Published: (2019-05-01)

Chromatographic study of sitagliptin and ertugliflozin under quality-by-design paradigm
by: Sunitha Gurrala, et al.
Published: (2023-06-01)

The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction
by: Lindsay Brust-Sisti, et al.
Published: (2022-11-01)

Novel stability-indicating RP-UPLC method for simultaneous estimation of sitagliptin and ertugliflozin in bulk and pharmaceutical formulations
by: Ramya kuber B, et al.
Published: (2021-04-01)

SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease
by: Swetha R. Kanduri, et al.
Published: (2020-08-01)

Hypertriglyceridemia in equines with refractory hyperinsulinemia treated with SGLT2 inhibitors
by: Eleanor M. Kellon, et al.
Published: (2023-06-01)

Safe and pragmatic use of sodium-glucose co-transporter 2 (SGLT 2) inhibitors: medication counseling
by: S. Kalra, et al.
Published: (2016-08-01)

Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
by: Alex Ali Sayour, et al.
Published: (2021-09-01)

Stability indicating method development and validation for simultaneous estimation and quantification of Ertugliflozin and Metformin in bulk and tablet dosage form
by: Bhawani Sunkara, et al.
Published: (2021-01-01)

Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors
by: Weronika Frąk, et al.
Published: (2023-07-01)

SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease
by: Manuel Alfredo Podestà, et al.
Published: (2023-01-01)

The Effects of SGLT2 Inhibitors on Liver Cirrhosis Patients with Refractory Ascites: A Literature Review
by: Yasunori Miyamoto, et al.
Published: (2023-03-01)

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
by: M. V. Karg, et al.
Published: (2018-01-01)

Neuroprotective Effect of SGLT2 Inhibitors
by: Agnieszka Pawlos, et al.
Published: (2021-11-01)

SGLT2i: beyond the glucose-lowering effect
by: Lihua Ni, et al.
Published: (2020-06-01)

Development and validation of stability-indicating RP-HPLC method for the simultaneous determination of ertugliflozin pidolate and metformin hydrochloride in bulk and tablets
by: K. Sravana Kumari, et al.
Published: (2020-10-01)

Electrocardiographic changes associated with SGLT2 inhibitors and non-SGLT2 inhibitors: A multi-center retrospective study
by: Victor Chien-Chia Wu, et al.
Published: (2022-09-01)

Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients
by: In-Chang Hwang, et al.
Published: (2020-05-01)

Milk Formula Enriched with Sodium Butyrate Influences Small Intestine Contractility in Neonatal Pigs
by: Monika Słupecka-Ziemilska, et al.
Published: (2022-10-01)

Impact of SGLT2 inhibitors treatment on the chronic kidney disease in people with type 2 diabetes
by: Marcin Czarkowski, et al.
Published: (2022-09-01)

Efficacy of sodium-glucose co-transporter-2 inhibitors in patients with heart failure
by: E. V. Kovalenko, et al.
Published: (2021-02-01)

Determining the Role of SGLT2 Inhibition with Dapagliflozin in the Development of Diabetic Retinopathy
by: Lakshini Y. Herat, et al.
Published: (2022-12-01)

Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches
by: Yu Zhang, et al.
Published: (2023-06-01)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis
by: Jonathan V. Mui, et al.
Published: (2021-10-01)

The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone
by: Yan-Rong Li, et al.
Published: (2021-08-01)

Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary
by: Annamaria Mascolo, et al.
Published: (2022-09-01)

Quality of methodological reporting of randomized clinical trials of sodium-glucose cotransporter-2 (sglt2) inhibitors
by: Hadeel Alfahmi, et al.
Published: (2017-01-01)

SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review
by: Merlin C Thomas, et al.
Published: (2023-08-01)

Crosstalk between Sodium–Glucose Cotransporter Inhibitors and Sodium–Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases
by: Al-Anood Al-Shamasi, et al.
Published: (2021-11-01)

Impact of Baseline Clinical Variables on SGLT2i’s Antiproteinuric Effect in Diabetic Kidney Disease
by: Irene Capelli, et al.
Published: (2023-04-01)

SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice
by: Damilola D. Adingupu, et al.
Published: (2019-02-01)

Cardiac Sodium/Hydrogen Exchanger (NHE11) as a Novel Potential Target for SGLT2i in Heart Failure: A Preliminary Study
by: Lorena Pérez-Carrillo, et al.
Published: (2022-09-01)

Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors
by: Lucia Scisciola, et al.
Published: (2023-02-01)